Document Type : Original Article(s)


1 Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

2 Assistant Professor, Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

3 Professor, Heart Failure Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

4 Associate Professor, Cancer Prevention Research Center, AND Department of Epidemiology and Biostat, School of Public Health, Isfahan University of Medical Sciences, Isfahan, Iran

5 Heart Failure Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

6 Assistant Professor, Endocrinologist, Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

7 Assistant Professor, Hypertension Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

8 Professor, Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran


BACKGROUND: Heart failure (HF) resulted from ultimate pathway of many cardiovascular diseases (CVDs) or as a separate entity poses a considerable increasing prevalence and economic burden, but its registry for better management is less frequently done. In this study, we aimed to design and implement HF registry.METHODS: Persian Registry Of cardioVascular diseasE (PROVE) was initiated from March 2015 and continuously collected information of patients suffering from HF, ST-elevation myocardial infarction (STEMI), atrial fibrillation (AF), percutaneous coronary intervention (PCI), stroke, familial hypercholesterolemia (FH), congenital heart disease (CHD), chronic ischemic cardiovascular disease (CICD), and acute coronary syndrome (ACS) from 18 different cardiac centers. Data of patients with HF were collected from their medical forms and recorded in a registry system of PROVE/HF plus telephone follow-up survey of 1, 6, and 12 months after the date of HF attack.RESULTS: Assessment of all related questions led to definition of a final questionnaire including 27 items regarding demographic information, underlying disorders and their complications, patients’ symptoms and signs, and laboratory and relevant para-clinic data at admission time, during hospitalization, and post discharge. Follow-up information was mostly based on patients’ general status and medication usage.CONCLUSION: PROVE execution was a successful and hopeful project providing data of major CVDs in order to design appropriate preventive actions and better management and treatment strategies plus a valuable data center being utilized in multiple future comprehensive projects. 


  1. Riegel B, Carlson B. Facilitators and barriers to heart failure self-care. Patient Educ Couns 2002; 46(4): 287-95.
  2. Garakyaraghi M, Givi M, Sadeghi M, Pourmoghaddas A, Alizadeh N. Erum myeloperoxidase level in patients with chronic heart failure. Iran Heart J 2015; 16(1): 20-5.
  3. Targonski R, Sadowski J, Starek-Stelmaszczyk M, Targonski R, Rynkiewicz A. Prognostic significance of red cell distribution width and its relation to increased pulmonary pressure and inflammation in acute heart failure. Cardiol J 2018.
  4. Raymond JL, Krause MV. Krause's food & nutrition therapy. Philadelphia, PA: Saunders/Elsevier; 2008.
  5. Sarrafzadegan N, Kelishadi R, Baghaei A, Hussein Sadri G, Malekafzali H, Mohammadifard N, et al. Metabolic syndrome: An emerging public health problem in Iranian women: Isfahan Healthy Heart Program. Int J Cardiol 2008; 131(1): 90-6.
  6. Gaziano TA, Bitton A, Anand S, Abrahams-Gessel S, Murphy A. Growing epidemic of coronary heart disease in low-and middle-income countries. Curr Probl Cardiol 2010; 35(2): 72-115.
  7. Alaei Faradonbeh N, Nikaeen F, Akbari M, Almasi N, Vakhshoori M. Cardiovascular disease risk prediction among Iranian patients with diabetes mellitus in Isfahan Province, Iran, in 2014, by using Framingham risk score, atherosclerotic cardiovascular disease risk score, and high-sensitive C-reactive protein. ARYA Atheroscler 2018; 14(4): 163-8.
  8. Sakata Y, Shimokawa H. Epidemiology of heart failure in Asia. Circ J 2013; 77(9): 2209-17.
  9. Komanduri S, Jadhao Y, Guduru SS, Cheriyath P, Wert Y. Prevalence and risk factors of heart failure in the USA: NHANES 2. J Community Hosp Intern Med Perspect 2017; 7(1): 15-20.
  10. Mahmood SS, Levy D, Vasan RS, Wang TJ. The Framingham heart study and the epidemiology of cardiovascular disease: A historical perspective. Lancet 2014; 383(9921): 999-1008.
  11. Givi M, Sarrafzadegan N, Garakyaraghi M, Yadegarfar G, Sadeghi M, Khosravi A, et al. Persian Registry Of cardioVascular diseasE (PROVE): Design and methodology. ARYA Atheroscler 2017; 13(5): 236-44.
  12. Jonsson A, Edner M, Alehagen U, Dahlstrom U. Heart failure registry: A valuable tool for improving the management of patients with heart failure. Eur J Heart Fail 2010; 12(1): 25-31.
  13. Laothavorn P, Hengrussamee K, Kanjanavanit R, Moleerergpoom W, Laorakpongse D, Pachirat O, et al. Thai Acute Decompensated Heart Failure Registry (Thai ADHERE). CVD Prev Control 2010; 5(3): 89-95.
  14. Givi M, Shafie D, Garakyaraghi M, Yadegarfar G, Roohafza HR, Ahmadi SA, et al. Patients characteristics and preliminary outcomes of heart failure registry in a middle-income country: Persian registry of cardiovascular disease/heart failure (PROVE/HF). GMJ 2018; 7: e1026.
  15. Huffman DA. An optimum method of coding an ensemble of messages consisting of a finite number of members is developed. A minimum-redundancy code is one constructed in such a way that the average number of coding digits per message is minimized. Proceedings of the IRE 1952; 40(9): 1098-101.
  16. Golin MJ, Kenyon C, Young NE. Huffman coding with unequal letter costs. Proceedings of the 34th Annual ACM Symposium on Theory of Computing; 2002 May 19-21; Quebec, Canada.
  17. Fonarow GC. The acute decompensated heart failure national registry (ADHERE): Opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med 2003; 4(Suppl 7): S21-S30.
  18. Atherton JJ, Hayward CS, Wan Ahmad WA, Kwok B, Jorge J, Hernandez AF, et al. Patient characteristics from a regional multicenter database of acute decompensated heart failure in Asia Pacific (ADHERE International-Asia Pacific). J Card Fail 2012; 18(1): 82-8.
  19. Schjodt I, Nakano A, Egstrup K, Cerqueira C. The Danish heart failure registry. Clin Epidemiol 2016; 8: 497-502.
  20. Filippatos G, Khan SS, Ambrosy AP, Cleland JG, Collins SP, Lam CS, et al. International registry to assess medical practice with longitudinal observation for treatment of heart failure (REPORT-HF): Rationale for and design of a global registry. Eur J Heart Fail 2015; 17(5): 527-33.
  21. Wang CC, Chang HY, Yin WH, Wu YW, Chu PH, Wu CC, et al. TSOC-HFrEF registry: A registry of hospitalized patients with decompensated systolic heart failure: Description of population and management. Acta Cardiol Sin 2016; 32(4): 400-11.
  22. Ferrari R. EURObeservational research programme. Eur Heart J 2010; 31(9): 1023-31.
  23. Giampaoli S, Hammar N, Adany R, De Peretti C. Population-based register of stroke: Manual of operations. Eur J Cardiovasc Prev Rehabil 2007; 14(Suppl 3): S23-S41.
  24. Gliklich RE, Dreyer NA, Leavy MB. Registries for evaluating patient outcomes: A user's guide. Rockville, MD: Agency for Healthcare Research and Quality; 2014.